Search for: "AstraZeneca AB" Results 1 - 20 of 85
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
7 Sep 2017, 9:59 pm by Patent Docs
AstraZeneca AB affirming the patentability of all challenged claims. [read post]
16 Apr 2015, 9:59 pm by Patent Docs
As set forth in the opinion, AstraZeneca's lawsuit against Apotex was part of the "second wave" of ANDA litigation, wherein the District Court apportioned into two sets of four defendants from the eight ANDA filers sued by AstraZeneca in the Southern District of New York starting at the end of the last century. [read post]
27 Oct 2013, 9:55 pm by Patent Docs
Astrazeneca AB et al. v. [read post]
8 Dec 2013, 8:02 pm by Patent Docs
Astrazeneca AB et al. v. [read post]
30 Dec 2013, 8:50 pm by Patent Docs
Noonan -- A classic example of product "evergreening" is how AstraZeneca used its experience with its omeprazole franchise (sold for over a decade as Prilosec®) to promote an alternative form of the drug, Nexium® (particularly, the S-omeprazole enantiomer) as "the little purple pill." [read post]
25 Mar 2012, 9:25 pm by Patent Docs
AstraZeneca AB et al v. [read post]
26 May 2012, 8:41 pm by Mark Summerfield
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520 (14 December 2011) Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142 (28 February 2012) Watson Pharma Pty Ltd v AstraZeneca AB [2012] FCA 200 (9 March 2012) Apotex Pty Ltd v AstraZeneca AB (No 3) [2012] FCA 265 (23 March 2012) AstraZenenca’s cholesterol drug CRESTOR will remain without generic competition in the Australian market for the foreseeable future, following a… [read post]
6 Dec 2012, 1:55 am
The General Court therefore reduced the amount of the fine imposed jointly and severally on AstraZeneca AB and AstraZeneca plc to €40.25 million and fixed the fine imposed on AstraZeneca AB at €12.25 million. [read post]
7 Aug 2011, 8:36 pm by Patent Docs
Astrazeneca AB et al. v. [read post]
16 Jul 2011, 1:42 am
Ranbaxy (UK) Ltd. v AstraZeneca AB [2011] EWHC 1831 (Pat) (15 July 2011) raises an interesting point on the interpretation of claims. [read post]
11 Mar 2012, 3:32 pm by Mark Summerfield
Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142 (28 February 2012) Watson Pharma Pty Ltd v AstraZeneca AB [2012] FCA 200 (9 March 2012) Interlocutory injunctions – prima facie case – balance of convenience – whether additional evidence provides grounds to vary previous findings At least five Australian pharmaceutical manufacturers are now ready to launch generic versions of cholesterol-lowering drug CRESTOR, while being barred from doing so… [read post]
24 Mar 2013, 8:01 pm by Patent Docs
AstraZeneca AB et al. v. [read post]
16 Aug 2009, 9:58 pm
Breath Ltd. 1:09-cv-04115; filed August 12, 2009 in the District Court of New Jersey • Plaintiffs: Astrazeneca LP; Astrazeneca AB • Defendant: Breath Ltd. [read post]
15 May 2012, 3:12 pm
457/10 P AstraZeneca AB and AstraZeneca plc v European Commission can be read in full here, The IPKat can't help admire the zeal and zest with which AstraZeneca has fought its corner, first on the question of liability and then on the quantum of the fine. [read post]
7 Mar 2012, 5:32 am by Mark Summerfield
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520 (14 December 2011) Interlocutory injunctions – prima facie case – balance of convenience – relevance of delay by patentee, complexity of proceedings, and parties’ conduct and obligations In the first Federal Court decision to follow the ruling of the Full Court in Samsung v Apple (see Samsung v Apple – A Closer Look at the Appeal Decision) Justice Rares has granted a preliminary injunction to pharmaceutical company… [read post]
16 Aug 2014, 11:39 pm by Mark Summerfield
AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99 (12 August 2014)An expanded panel of five judges of the Federal Court of Australia has held that two patents owned by AstraZeneca relating to the cholesterol-lowering drug marketed as CRESTOR (active ingredient rosuvastatin) are invalid. [read post]